JILL MCLEOD: Open Payments
NPI 1306031406 · MERCED, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$423 in 18 payments from 11 companies in 2025. Trend: 2023 $992 · 2024 $540 · 2025 $423
Food & beverage: $423
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $82 |
| Novartis Pharmaceuticals Corporation | 3 | $73 |
| Amgen Inc. | 2 | $48 |
| UCB, Inc. | 2 | $47 |
| LEO Pharma Inc. | 1 | $37 |
| Organon LLC | 2 | $35 |
| Incyte Corporation | 1 | $25 |
| Lilly USA, LLC | 1 | $22 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $21 |
| Biofrontera Inc. | 1 | $20 |
Products named: SKYRIZI, COSENTYX, Otezla, Bimzelx, ADBRY, VTAMA, OPZELURA, EBGLYSS.
Industry payments across CA — which companies pay providers there.
